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Five patients with disorders 
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The GCM2 gene encodes a transcription factor predominantly expressed in parathyroid cells that is 
known to be critical for development, proliferation and maintenance of the parathyroid cells. A cohort 
of 127 Spanish patients with a disorder of calcium metabolism were screened for mutations by Next‑
Generation Sequencing (NGS). A targeted panel for disorders of calcium and phosphorus metabolism 
was designed to include 65 genes associated with these disorders. We observed two variants of 
uncertain significance (p.(Ser487Phe) and p.Asn315Asp), one likely pathogenic (p.Val382Met) and 
one benign variant (p.Ala393_Gln395dup) in the GCM2 gene in the heterozygous state in five families 
(two index cases had hypocalcemia and hypoparathyroidism, respectively, and three index cases had 
primary hyperparathyroidism). Our study shows the utility of NGS in unravelling the genetic origin 
of some disorders of the calcium and phosphorus metabolism, and confirms the GCM2 gene as an 
important element for the maintenance of calcium homeostasis. Importantly, a novel variant in the 
GCM2 gene (p.(Ser487Phe)) has been found in a patient with hypocalcemia.
Calcium  (Ca2+) is required for many physiological functions (muscle contraction, nerve conduction, hormone 
release, mineralization of bone, and blood coagulation).  Ca2+ metabolism maintains a dynamic balance between 
intestinal absorption, exchange with the bone, and renal excretion. Parathyroid hormone (PTH), vitamin D 
and calcitonin regulate this balance by acting on their targets: intestine, bone and renal tubule. PTH is secreted 
by the parathyroid glands. The GCM2 gene (glial cells missing transcription factor 2, MIM *603716) encodes 
a transcription factor predominantly expressed in parathyroid  cells1,2. This transcription factor is known to be 
critical for development of the parathyroid cells and plays a critical role in adult parathyroid cell proliferation 
and  maintenance3,4. Thus, it has been demonstrated that a GCM2-deficient mouse lacked parathyroid  glands5.
The GCM2 gene was mapped to chromosome 6p24.22 and encodes the chorion-specific transcription factor 
GCMb. The full-length protein (506 amino acids) contains a N-terminal Zn-containing DNA binding domain 
(amino acids from 19 to 174), a nuclear localization sequence (amino acids from 176 to 191), a C-terminal 
conserved inhibitory domain (CCID, amino acids from 379 to 395), and two transcriptional activation domains 
in the C-terminal region: TAD1 (amino acids from 175 to 263) and TAD2 (amino acids from 428 to 506)2,6–8.
Loss-of-function mutations in the GCM2 gene have recently been described in humans as a rare cause of 
autosomal dominant or recessive familial isolated type 2 hypoparathyroidism (MIM #618883)6. Patients usually 
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develop seizures due to the hypocalcemia, in early life, with hyperphosphatemia, low to undetectable serum PTH 
levels and normal levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. On the other hand, gain-of-
function mutations in the GCM2 gene cause autosomal dominant hyperparathyroidism type 4 (MIM #617343)9, 
a disorder characterized by hypercalcemia and elevated or inappropriate PTH secretion by parathyroid glands.
In the present study, we report a novel variant of uncertain significance in the GCM2 gene in a family from 
Spain with severe hypocalcemia. Moreover, we report three previously described GCM2 gene variants, one likely 
pathogenic, one of uncertain significance and one benign, in four families from Spain presenting with different 
disorders of calcium metabolism.
Materials and methods
Ethics statement. The study was approved by the Ethics Committee for Clinical Research of Euskadi 
(CEIC-E). Patients and their participating relatives provided written informed consent for the genetic study. 
The research was carried out in accordance with the Declaration of Helsinki on human experimentation of the 
World Medical Association.
Patients. A total of 65 genes whose mutations are a recognized cause of calcium and phosphorus metabo-
lism disorders were tested by a Next-Generation Sequencing (NGS) panel in a cohort of 127 Spanish patients 
(50 had hypocalciuric hypercalcemia, 44 were diagnosed of primary hyperparathyroidism, 13 presented with 
hypocalcemia and/or hypoparathyroidism, 12 were diagnosed of pseudohypoparathyroidism and 8 had rickets). 
Clinical diagnoses were made by adult and pediatric endocrinologists. In all cases, the molecular analysis was 
done in the Molecular Genetic Laboratory at Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
From the whole cohort, five index cases with a suspected disorder of calcium metabolism (GS0198, CA0117, 
ME0292, ME0371 and CA0103) presented with GCM2 gene variants (Fig. 1).
Index case GS0198 was a 7-month-old child who was referred for evaluation of irritability and refusal to eat. 
He had suffered three episodes of seizures accompanied by rapid and involuntary muscle contractions. Labora-
tory results showed low serum  Ca2+ (less than 5 mg/dL, reference range 8.5–10.4) and 25-hydroxyvitamin D 
(7.49 ng/mL, reference range 9–47), and high serum phosphate (11.7 mg/dL, reference range 2.6–4.8), whereas 
serum intact PTH levels (54 pg/mL, reference range 10–65) were within the normal range. In addition, he pre-
sented with moderate hypomagnesemia (1.39 mg/dL, reference range 1.7–2.5). While the mother had normal 
calcium and phosphate metabolism, proband’s father had small stature (1.57 cm) and body segment dispar-
ity (short lower limbs). He had normal levels of serum  Ca2+ (9 mg/dL), phosphate (3.18 mg/dL), magnesium 
(1.94 mg/dL), intact PTH (34.38 pg/mL) and 25-hydroxyvitamin D (30.4 ng/mL) (Fig. 1a).
Index case CA0117 was a 65-year-old male who had hypocalcemia and hypoparathyroidism. He had osteoar-
thritis and suffered tingling of fingers and toes. Moreover, he was diagnosed with glaucoma. Laboratory results 
showed low serum  Ca2+ (5.4 mg/dL) and serum intact PTH (5.8 pg/mL), whereas 25-hydroxyvitamin D (24 ng/
Figure 1.  Pedigree of 5 families with variants in the GCM2 gene. The novel variant is marked in bold. Index 
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mL) and serum phosphate (4.3 mg/dL) were within the normal range. He was treated with calcium and vitamin 
D supplements. Regarding family history, there was no history of hypoparathyroidism or hypocalcemia (Fig. 1b).
Index case ME0292 was a 67-year-old male presenting with elevated serum intact PTH levels, hypophos-
phatemia, normocalcemia with vitamin D deficiency, hypercalciuria, and nephrolithiasis. Laboratory evaluation 
showed normal serum calcium (10.2 mg/dL), high intact PTH (95.6 pg/mL), low serum phosphate (2 mg/dL), and 
25-hydroxyvitamin D levels of 11 ng/mL. In addition, he exhibited high urinary calcium excretion (386 mg/24 h, 
reference range in adult male < 300 mg/24 h). Furthermore, index case ME0292 had a personal history of ankylos-
ing spondylitis, prostate gland enlargement, hepatic steatosis, and hyperlipidemia. He was diagnosed of primary 
hyperparathyroidism and parathyroid glands surgery was performed. Parathyroid hyperplasia of two superior 
glands was verified histologically and both were removed. However, after the surgical intervention, he contin-
ued with high intact PTH levels (113 pg/mL). He had a 61 year-old sister who had hyperparathyroidism (intact 
PTH 103 pg/mL) and nephrolithiasis as well (Fig. 1c). She had normal serum  Ca2+ (9.4 mg/dL), normal serum 
phosphate (3.1 mg/dL) and exhibited slightly high urinary  Ca2+ excretion (288 mg/24 h, reference range in adult 
women < 250 mg/24 h).
Index case ME0371 was a 17 year-old female who showed persistent hypercalcemia (serum  Ca2+ 11.5 mg/
dL), very high intact PTH (317 pg/mL), and normal serum phosphate (3.5 mg/dL). The patient exhibited high 
urinary  Ca2+ excretion (329 mg/24 h) and slightly low urinary phosphate excretion of 329 mg/24 h (reference 
range 350–1000). The parathyroid scintigraphy with Technetium 99m-sestamibi (Tc99m-MIBI) was normal. 
Regarding family history, there was no history of hyperparathyroidism or hypercalcemia (Fig. 1d).
Finally, index case CA0103 was a 69 year-old male who showed normal serum  Ca2+ (9.5 mg/dL), high intact 
PTH (140–200 pg/mL), and normal serum phosphate (3.2 mg/dL). The parathyroid scintigraphy with Techne-
tium 99 m-sestamibi suggested a left parathyroid adenoma. The patient exhibited low urinary  Ca2+ excretion 
(70 mg/24 h). Additionally, he had stage 3 chronic kidney disease which was stable in the last 15 years, and expe-
rienced an isolated episode of urinary lithiasis at 20 years of age. The last renal ultrasound performed was normal. 
Regarding family history, there was no history of hyperparathyroidism or chronic kidney disease (Fig. 1e).
DNA analysis. We used the MagPurix instrument for genomic DNA extraction from peripheral blood leu-
kocytes (Zinexts Life Science Corp., New Taipei City, Taiwan, R.O.C.). DNA purity and concentration were then 
determined using Qubit 2.0 fluorometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA).
For Next-Generation Sequencing, a targeted panel for disorders of calcium and phosphorus metabolism 
was designed to include 65 genes associated with these disorders (GNAS, STX16, PRKAR1A, PDE4D, PTHR1, 
PDE3A, PTHLH, CREB1, HDAC4, TRPS1, EXT1, HOXD13, ACVR1, GALNT3, LEP, LEPR, POMC, MC4R, 
TSHR, CASR, GNA11, AP2S1, MEN1, CDKN1A, CDKN1B, CDKN2B, CDKN2C, RET, CDC73, GCM2, CCND1, 
AIP, CTNNB1, EZH2, ZFX, DICER1, SDHB, SDHC, SDHD, CYP27B1, VDR, CYP2R1, CYP24A1, PTH, TBX1, 
NEBL, AIRE, GATA3, HADHB, TBCE, FAM111A, SOX3, DMP1, FGF23, SLC34A3, PHEX, SLC34A1, SLC9A3R1, 
ENPP1, TRPM6, CLDN16, CLDN19, ALPL, FXYD2 and CNNM2). The panel design was performed by Ion 
AmpliSeq Designer (Thermo Fisher Scientific). PubMed (https ://www.ncbi.nlm.nih.gov/pubme d/) was consulted 
to select the genes included in the panel. Library preparation was done using the Ion Ampliseq Library Kit v2.0 
(Thermo Fisher Scientific) according to manufacturer’s instructions. Samples were then sequenced using the 
Ion GeneStudio S5 System (Thermo Fisher Scientific). Base calling, read filtering, alignment to the reference 
human genome GRCh37/hg19, and variant calling were done using Ion Torrent Suite and Ion Reporter Software 
(Thermo Fisher Scientific).
Variants described in this article were tested by polymerase chain reaction (PCR), sequenced with fluorescent 
dideoxynucleotides (BigDye Terminator v3.1 Cycle Sequencing Kit, Life Technologies, Grand Island, NY, USA), 
and loaded onto an ABI3130xl Genetic Analyzer (Thermo Fisher Scientific).
DNA variants were named according to the Human Genome Variation Society guidelines (http://www.hgvs.
org) and classified according to ACMG-AMP (American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology)  guidelines10.
As a measure of association between genotype and phenotype, we used Odds Ratio (OR). OR values above 
1 mean there is an association between the variant and the risk of disease, while values below 1 mean there is a 
negative association between the variant and the risk of disease. If the 95% confidence interval for an OR includes 
1, it means the results are not statistically  significant10. We used the DJR Hutchon calculator for confidence 
intervals of odds ratio (http://www.hutch on.net/Confi dOR.htm).
Results
Regarding molecular diagnosis, we observed four variants in the GCM2 gene. One novel variant of uncertain 
significance (c.1460C > T; p.(Ser487Phe)), and three previously reported variants; one variant of uncertain sig-
nificance (c.943A>G; p.Asn315Asp), one likely pathogenic variant (c.1144G>A; p.Val382Met) and, finally, one 
benign variant (c.1185_1186insGCC TAC CAG; p.Ala393_Gln395dup), all in the heterozygous state (Table 1 
and Fig. 2).
Index case GS0198 had the p.(Ser487Phe) variant (Fig. 1a II1). According to ACMG-AMP guidelines, this 
variant is classified of uncertain significance (Table 2). This variant has not been found in the population database 
frequencies checked (GnomAD, ExAc, dbSNP, and 1000G), and occurs at a position within an important domain 
for the transcriptional function of the protein, near the C-terminus. Moreover, the serine residue at codon 487, 
located within the transcriptional activation domain 2 (TAD2), involves substitution of a polar neutral serine 
for the hydrophobic aromatic phenylalanine, probably disturbing the normal function of the protein. His father, 
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Table 1.  GCM2 variants identified in patients. *Numbering is according to DNA sequence (Ensembl: 
ENST00000379491.5), all in heterozygous. TAD1 transcriptional activation domain 1, TAD2 transcriptional 
activation domain 2, CCID C-terminal conserved inhibitory domain.
Family
Number of 
individuals with the 
variant Nucleotide change* Amino acid change* Exon Domain Phenotype Variant class References








ME0292 1 c.1144G>A p.Val382Met 5 CCID Primary hyperpar-athyroidism Likely pathogenic
11
CA0117 3 c.1185_1186insGCC TAC CAG p.Ala393_Gln395dup 5 CCID Hypoparathyroidsm Benign
12
GS0198 2 c.1460C>T p.(Ser487Phe) 5 TAD2 Hypocalcemia Uncertain significance This study
Figure 2.  Schematic representation of the GCM2 gene, representing the position of 3 missense variants and 
one short duplication. Variant marked in bold has not been reported to date. TAD1 transcriptional activation 
domain 1, TAD2 transcriptional activation domain 2, CCID C-terminal conserved inhibitory domain.
Table 2.  GCM2 variants classification according to the ACMG guidelines. *Numbering is according to DNA 
sequence (Ensembl: ENST00000379491.5 for the GCM2 gene), all in heterozygous. TAD2 transcriptional 
activation domain 2, CCID C-terminal conserved inhibitory domain, PS strong evidence of pathogenicity, PM 
moderate evidence of pathogenicity, PP supporting evidence of pathogenicity, BS strong evidence of benign 
impact, BP supporting evidence of benign impact.
Gene Nucleotide change* Amino acid change* Selected criteria for pathogenic variants Selected criteria for benign variants Variant class
GCM2 c.943A>G p.Asn315Asp
PS3: Well-established in vitro functional 
studies supportive of a damaging effect on 
the gene product (20% more activity than 
wild-type protein)
BP6: Reputable source recently reports 
variant as benign but the evidence is not 
available to the laboratory to perform 




PS3: Well-established in vitro functional 
studies supportive of a damaging effect on 
the gene product (2.1 times higher activity 
than wild-type protein)
PM1: Located in a well-established func-
tional domain (CCID)
PP5: Reported as pathogenic
– Likely pathogenic
GCM2 c.1185_1186insGCC TAC CAG p.Ala393_Gln395dup
PM1: Located in a well-established func-
tional domain (CCID)
PM4: Protein length changes as a result 
of in-frame duplication in a non-repeat 
region
BS1: Allele frequency is greater than 
expected for disorder
BS3: Well-established in vitro functional 
studies show no damaging effect on 
protein function
BP6: Reputable source recently reports 
variant as benign but the evidence is not 
available to the laboratory to perform 
an independent evaluation (Reported in 
ClinVar as benign and likely benign)
Benign
GCM2 c.1460C>T p.(Ser487Phe)
PM1: Located in a well-established func-
tional domain (TAD2)
PM2: Absent from controls in Exome 
Sequencing Project, 1000 Genomes Pro-





Scientific Reports |         (2021) 11:2968  | https://doi.org/10.1038/s41598-021-82661-y
www.nature.com/scientificreports/
We found two variants within the C-terminal conserved inhibitory domain CCID (p.Ala393_Gln395dup and 
p.Val382Met). Index case CA0117 had the variant p.Ala393_Gln395dup in the heterozygous state (Fig. 1b I1). 
This duplication, which is not in a repeat region, is located within an important regulatory region (the conserved 
inhibitory domain). It has been found in the population database frequencies checked with a low frequency 
(highest population Minor Allele Frequency (MAF): 0.01). Moreover, it has been observed in four adults in 
the homozygous state (GnomAD exomes). Furthermore, functional studies showed that this duplication has 
a transcriptional activity similar to wild-type  protein12. In addition, we found this duplication in the patient’s 
two asymptomatic daughters in the heterozygous state as well (Fig. 1b II1, II2). This duplication is classified as 
benign according to ACMG-AMP guidelines (Table 2). Importantly, NGS analysis showed a second rare vari-
ant in index case CA0117. A heterozygous PTH1R variant (c.1168C>T; p.(Arg390Trp)) in exon 13 (Ensembl: 
ENST00000449590.6) was identified. This variant is not inherited by his two asymptomatic daughters. The PTH1R 
gene (MIM *168468) encodes the parathyroid hormone/parathyroid hormone related peptide receptor (PTH1R) 
that is a G-protein couple receptor for PTH and PTHLH (parathyroid hormone-like hormone) 13. This variant has 
a MAF < 0.01. The software Varsome 14 classified this variant as of uncertain significance according to ACMG-
AMP guidelines (Table 3). PTH1R has 7 potential membrane-spanning domains and this variant occurs at a 
not conserved position located within a cytoplasmic topological domain (amino acids from 383 to 409) within 
this region (UniProtKB: Q03431) 15. Mutations in the PTH1R gene are known to cause Jansen’s metaphyseal 
chondrodysplasia (MIM #156400), chondrodysplasia Blomstrand type (MIM #215045), Eiken syndrome (MIM 
#600002), and failure of tooth eruption (MIM #125350). However, our patient does not have clinical character-
istics compatible with these diseases.
Index case ME0292 had the missense p.Val382Met variant located in the CCID (Fig. 1c II1). This variant 
has a MAF < 0.01 and was previously found in a parathyroid adenoma 11. Functional studies showed that this 
variant has 2.1 times higher transcriptional activity than wild-type 6. Therefore, p.Val382Met is considered an 
activation variant. In addition, NGS analysis showed a second rare variant in index case ME0292 in the SLC34A1 
gene (c.272_292del21; p.Val91_Ala97del) in the heterozygous state. The SLC34A1 gene encodes the Sodium-
dependent phosphate transport protein 2a (NaPi-2a, MIM * 182309) that is located in the apical membrane of 
renal proximal tubular cells 16. Mutations in this gene are associated with different clinical disease phenotypes; 
autosomal recessive form of infantile hypercalcemia type 2 (MIM # 616963) or Fanconi renotubular syndrome 
type 2 (MIM # 613388), and with autosomal dominant hypophosphatemic nephrolithiasis/osteoporosis type 1 
(MIM # 612286). This small deletion in exon 4 (Ensembl: ENST00000324417.6) has been previously described 
in patients who presented with nephrolithiasis 17–19. Functional studies showed a reduction in the expression 
of this deletion in HEK293 cells, and a significantly reduction in phosphate transport compared with wild-type 
NaPi-2a in Xenopus oocytes 19. On the other hand, it is a relatively common deletion with a highest population 
MAF of 0.05. The proband’s sister only had the p.Val91_Ala97del variant in SLC34A1 in the heterozygous state. 
She presented with nephrolithiasis (Fig. 1c II2).
Finally, we found the p.Asn315Asp variant in the GCM2 gene in the index cases ME0371 and CA0103 (Fig. 1d 
II1 and Fig. 1e II1, respectively) near the CCID. This variant has a MAF of 0.02 and it has been previously classi-
fied as benign or likely benign (ClinVar: VCV000712319.3). Functional studies showed that this variant has a 20% 
more transcriptional activity than the wild-type 6. Furthermore, it has been found in patients with parathyroid 
adenomas and hyperplasia 20. The asymptomatic mother of index case ME0371 had the p.Asn315Asp variant 
(Fig. 1d I2). In our cohort, we found two alleles with the variant p.Asn315Asp out of 88 alleles (44 patients with 
primary hyperparathyroidism analyzed by NGS). Compared with data of gnomAD for Non-Finnish European 
(481/129204), we observed an enrichment of this variant in patients with primary hyperparathyroidism in our 
Table 3.  Classification of PTH1R and SLC34A1 variants according to the ACMG guidelines. * Numbering 
is according to DNA sequence (Ensembl: ENST00000449590.6 for the PTH1R gene and Ensembl: 
ENST00000324417.5 for the SLC34A1 gene), all in heterozygous; PS, Strong evidence of pathogenicity; PM, 
Moderate evidence of pathogenicity; PP, Supporting evidence of pathogenicity; BP, Supporting evidence of 
benign impact.
Gene Nucleotide change* Amino acid change*
Selected criteria for pathogenic 
variants Selected criteria for benign variants Variant class
PTH1R c.1168C>T p.Arg390Trp
PM2: Low frequency in ExAC 
(2/120788) and GnomAD-Exomes 
(5/251282)
PP2: Missense variant in a gene that 
has a low rate of benign missense 
variation and in which missense 
variants are a common mechanism 
of disease
– Uncertain significance
SLC34A1 c.272_292delTCC CCA AGC TGC GCC AGG CTG p.Val91_Ala97del
PS3: Well-established in vitro 
functional studies supportive of a 
damaging effect on the gene product 
(functional analyses confirmed the 
impaired trafficking in HEK293 cells)
PM4: Protein length changes as a 
result of in-frame deletions in a non-
repeat region
PP5: Reported as pathogenic
BP6: Reputable source recently 
reports variant as benign but the 
evidence is not available to the 
laboratory to perform an independ-
ent evaluation (ClinVar classifies this 
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cohort [Odds Ratio (OR): 6.1049, Confidence Interval IC95% (1.49–24.86)]. According to ACMG-AMP guide-
lines, we classified this variant as of uncertain significance (Table 2).
Discussion
In this study, we describe five families who had variants in the GCM2 gene. The complete genetic study revealed 
one novel variant of uncertain significance (c.1460C>T; p.(Ser487Phe)), and three previously reported variants; 
one of uncertain significance (c.943A>G; p.Asn315Asp), one likely pathogenic variant (c.1144G>A; p.Val382Met) 
and, finally, one benign variant (c.1185_1186insGCC TAC CAG; p.Ala393_Gln395dup), all in the heterozygous 
state. In addition, the genetic study revealed other two variants located in the PTH1R and SLC34A1 genes, of 
uncertain significance and likely pathogenic respectively, both in the heterozygous state as well (Table 3).
So far, according to the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk), 14 variants in the 
GCM2 gene have been reported associated with hypoparathyroidism. These 14 variants were considered as 
loss-of-function mutations. In our genetic study, two variants in the GCM2 gene were found in two patients 
with hypocalcemia (GS0198) and hypoparathyroidism (CA0117). Index case GS0198 and his father had the 
missense p.(Ser487Phe) variant in the heterozygous state located within the TAD2 (Fig. 2). As far as we know, 
only another missense mutation within the TAD2 (p.Asn502His) has been reported 21. Furthermore, a dominant-
negative effect produced by two small deletions affecting the TAD2, p.(His465Thrfs*66) and p.(Pro467Glnfs*64), 
has been described by other studies 22. The p.Asn502His variant showed a reduction in transactivation and it 
was found in the heterozygous state in one patient diagnosed at 5 days of age, presenting with hypocalcemia, 
hyperphosphatemia, hypomagnesemia, low 25-OH vitamin D levels and normal serum intact PTH levels. The 
same clinical features were observed in our index case GS0198 who had the p.(Ser487Phe) variant. Moreover, 
the p.Asn502His variant showed a dominant-negative effect 21. In the family previously described, the proband’s 
father had the p.Asn502His variant in the heterozygous state as well 21. He only presented with finger paresthesia 
and mild hypocalcemia (8.14 mg/dL), while index case GS0198’s father had small stature and body segment 
disparity. These two variants, p.(Ser487Phe) and p.Asn502His, could produce a similar effect in the protein in 
the heterozygous state.
Index case CA0117 had the p.Ala393_Gln395dup variant, which is located within the CCID (Fig. 2). As 
far as we know, only one polymorphism showing a reduced transcriptional activity (10% reduction) has been 
described in the heterozygous state in this domain (p.Lys388Gln) 12. The p.Ala393_Gln395dup duplication 
observed in index case CA0117 and his two asymptomatic daughters produces an extension of the inhibitory 
region. Functional studies showed a similar activity than the wild-type protein 12. Moreover, this duplication is 
maybe common to be a pathogenic mutation (1% in some populations). On the other hand, this duplication is 
enriched in our cohort [OR: 59.15 (IC95% 13.92–251.2)] compared with a control population of Non-Finnish 
European [gnomAD (168/129188)]. We performed genetic analysis by NGS in 127 patients (254 alleles). Thirteen 
had hypocalcemia/hypoparathyroidism (26 alleles). Only two patients with hypocalcemia (one of them is not 
included in the manuscript) had the p.Ala393_Gln395dup duplication in the GCM2 gene (2/26).
Three gain-of-function mutations located in the CCID (p.Leu379Gln, p.Lys388Glu and p.Tyr394Ser) with 3.3, 
2.1 and 2.4 times higher activity in the heterozygous state, respectively 12 and two disease-associated polymor-
phisms (p.Arg59Cys and p.Tyr282Asp) have been previously described associated with hyperparathyroidism. 
In our cohort, we found one likely gain-of-function mutation (p.Val382Met). The p.Val382Met variant, which is 
located in the CCID, was previously reported in a parathyroid adenoma 11. Functional studies performed in the 
CCID demonstrated that this variant has 2.1 times higher activity than wild-type 6. Therefore, the p.Val382Met 
variant caused the parathyroid hyperplasia observed in index case ME0292.
A few variants out of the CCID, p.Gln330Leu and p.Arg406Gln, have been reported in patients with primary 
hyperparathyroidism 20. Functional analysis in p.Asn315Asp, present in our cohort, and also located out of the 
CCID (Fig. 2), showed that it has a 20% more transcriptional activity than the wild-type 6. Furthermore, it has 
been found in patients with parathyroid adenomas and hyperplasia 20. Thus, we hypothesize that the p.Asn315Asp 
variant may cause the hyperparathyroidism present in index cases ME0371 and CA0103. On the other hand, the 
asymptomatic mother of index case ME0371 had the p.Asn315Asp variant, and this is in line with the phenotype 
variability within the family previously observed. Instead, penetrance seems to be low, so it has been suggested 
that the majority of individuals with gain-of-function variants in the GCM2 gene will not develop a parathyroid 
adenoma 23.
Importantly, the genetic study showed a second variant in index case CA0117. The p.(Arg390Trp) vari-
ant, located in the heterozygous state in the PTH1R gene, is not inherited by his two daughters. This variant is 
located in a cytoplasmic region between the 5 and 6 transmembrane domains. Pathogenic mutations within the 
transmembrane domain have been associated with Murk Jansen Chondrodysplasia. Thus, patients with reces-
sive mutations presented with mild hypercalcemia, hypophosphatemia, low intact PTH levels, hypercalciuria, 
bone dysplasia, kidney stones, bowing and osteopenia. On the other hand, patients with dominant mutations 
presented with a milder form of the disease, with less severe skeletal and mineral ion abnormalities 24. Moreover, 
it has been described that some polymorphisms in the PTH1R gene can determine the sensitivity of the kidney 
and bone to the catabolic or anabolic action of PTH 25. This variant is not located in an important domain for 
binding to PTH, PTHLH or the signalling initiator G protein and the patient does not present symptoms compat-
ible with diseases associated with pathogenic variants in the PTH1R gene. Therefore, it is unlikely to influence 
the phenotype of the patient.
On the other hand, index case ME0292’s sister presented with high intact PTH levels and nephrolithiasis 
without other remarkable symptoms. She does not have the p.Val382Met variant in the GCM2 gene. However, 
we observed another variant in the SLC34A1 gene in the index case ME0292 and his sister in the heterozygous 
state (p.Val91_Ala97del). Despite the p.Val91_Ala97del deletion is frequent in general population (MAF of 0.01), 
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functional studies demonstrated that it exhibits a significantly reduced phosphate transport compared with 
wild-type, and considering the high prevalence of people globally being affected by kidney stones (1–15%)26, 
we cannot exclude that this deletion may cause nephrolithiasis in family ME0292.
Our study shows the utility of NGS in unravelling the genetic origin of disorders in the calcium and phospho-
rus metabolism. Moreover, our results confirmed GCMb as an important genetic element for the maintenance 
of calcium homeostasis, as it interacts with genes involved in the calcium metabolism such as CASR, modifying 
its expression, and GATA3 and MAFB modifying PTH expression 4. However, the penetrance seems to be low 
probably because some mechanisms of compensation occur 20.
In conclusion, this study identified four variants in the GCM2 gene, of which one was novel (p.(Ser487Phe)) 
and classified as a variant of uncertain significance. Further studies aimed at the functional characterization of 
this variant will be of help in defining the hypothesized pathogenic role.
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